Fig. 5.

Effect of various TLR agonists on BiVax immunization. a Mice (3 per group) were immunized i.v. on days 0 and 12 with Pam2-Trp1 peptide and one of the following TLR agonists: 50 μg poly-IC, 100 μg CpG-1826, 100 μg CpG-1585, 50 μg poly-AU, 100 μg Pam3CSK4, and a mixture of poly-IC + CpG-1826. On day 7 (post-prime) and 19 (post-boost), blood samples were evaluated by tetramer analysis. b Mice (3 per group) were immunized i.v. on days 0 and 12 with BiVax/CpG-1826, and boosted one more time with BiVax/poly-IC on day 24. The presence of antigen-specific CD8 T cells in blood was evaluated by tetramer analysis on days 7 (post-prime), 19 (post-boost), and 31 (post-2nd boost). Points, the value for each individual mouse; horizontal line, the average value of the group; bars, SD